Attached files

file filename
EX-32.2 - EX-32.2 - Cogent Biosciences, Inc.cogt-ex322_8.htm
EX-31.2 - EX-31.2 - Cogent Biosciences, Inc.cogt-ex312_7.htm
EX-31.1 - EX-31.1 - Cogent Biosciences, Inc.cogt-ex311_10.htm
10-Q - 10-Q - Cogent Biosciences, Inc.cogt-10q_20210331.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cogent Biosciences, Inc. (the “Company”) for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Andrew Robbins, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 12, 2021

By:

 

/s/ Andrew Robbins

 

 

 

Andrew Robbins

 

 

 

Chief Executive Officer and President

(Principal Executive Officer)